Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2012 Apr 18;2012(4):CD004426.
doi: 10.1002/14651858.CD004426.pub3.

Treatment for mitochondrial disorders

Gerald Pfeffer  1 , Kari Majamaa, Douglass M Turnbull, David Thorburn, Patrick F Chinnery
Affiliations
Meta-Analysis

Treatment for mitochondrial disorders

Gerald Pfeffer et al. Cochrane Database Syst Rev. .

Abstract

Background: Mitochondrial respiratory chain disorders are the most prevalent group of inherited neurometabolic diseases. They present with central and peripheral neurological features usually in association with other organ involvement including the eye, the heart, the liver, and kidneys, diabetes mellitus and sensorineural deafness. Current treatment is largely supportive and the disorders progress relentlessly causing significant morbidity and premature death. Vitamin supplements, pharmacological agents and exercise therapy have been used in isolated cases and small clinical trials, but the efficacy of these interventions is unclear. The first review was carried out in 2003, and identified six clinical trials. This major update was carried out to identify new studies and grade the original studies for potential bias in accordance with revised Cochrane Collaboration guidelines.

Objectives: To determine whether there is objective evidence to support the use of current treatments for mitochondrial disease.

Search methods: We searched the Cochrane Neuromuscular Disease Group Specialized Register (4 July 2011), CENTRAL (2011, Issue 2, MEDLINE (1966 to July 2011), and EMBASE (January 1980 to July 2011), and contacted experts in the field.

Selection criteria: We included randomised controlled trials (including cross-over studies). Two of the authors independently selected abstracts for further detailed review. Further review was performed independently by all five authors to decide which trials fit the inclusion criteria and graded risk of bias. Participants included males and females of any age with a confirmed diagnosis of mitochondrial disease based upon muscle histochemistry, respiratory chain complex analysis of tissues or cell lines or DNA studies. Interventions included any pharmacological agent, dietary modification, nutritional supplement, exercise therapy or other treatment. The review authors excluded studies at high risk of bias in any category. The primary outcome measures included an change in muscle strength and/or endurance, or neurological clinical features. Secondary outcome measures included quality of life assessments, biochemical markers of disease and negative outcomes.

Data collection and analysis: Two of the authors (GP and PFC) independently identified studies for further evaluation from all abstracts within the search period. For those studies identified for further review, all five authors then independently assessed which studies met the entry criteria. For the included studies, we extracted details of the number of randomised participants, treatment, study design, study category, allocation concealment and other risk of bias criteria, and participant characteristics. Analysis was based on intention-to-treat data. We planned to use meta-analysis, but this did not prove necessary.

Main results: The authors reviewed 1335 abstracts, and from these identified 21 potentially eligible abstracts. Upon detailed review, 12 studies fulfilled the entry criteria. Of these, eight were new studies that had been published since the previous version of this review. Two studies which were included in the previous version of this review were excluded because of potential for bias. The comparability of the included studies is extremely low because of differences in the specific diseases studied, differences in the therapeutic agents used, dosage, study design, and outcomes. The methodological quality of included studies was generally high, although risk of bias was unclear in random sequence generation and allocation concealment for most studies. Otherwise, the risk of bias was low for most studies in the other categories. Serious adverse events were uncommon, except for peripheral nerve toxicity in a long-term trial of dichloroacetate (DCA) in adults.One trial studied high-dose coenzyme Q10 without clinically meaningful improvement (although there were multiple biochemical, physiologic, and neuroimaging outcomes, in 30 participants). Three trials used creatine monohydrate alone, with one reporting evidence of improved measures of muscle strength and post-exercise lactate, but the other two reported no benefit (total of 38 participants). One trial studied the effects of a combination of coenzyme Q10, creatine monohydrate, and lipoic acid and reported a statistically significant improvement in biochemical markers and peak ankle dorsiflexion strength, but overall no clinical improvement in 16 participants. Five trials studied the effects of DCA: three trials in children showed a statistically significant improvement in secondary outcome measures of mitochondrial metabolism (venous lactate in three trials, and magnetic resonance spectroscopy (MRS) in one trial; total of 63 participants). One trial of short-term DCA in adults demonstrated no clinically relevant improvement (improved venous lactate but no change in physiologic, imaging, or questionnaire findings, in eight participants). One longer-term DCA trial in adults was terminated prematurely due to peripheral nerve toxicity without clinical benefit (assessments included the GATE score, venous lactate and MRS, in 30 participants). One trial using dimethylglycine showed no significant effect (measurements of venous lactate and oxygen consumption (VO(2)) in five participants). One trial using a whey-based supplement showed statistically significant improvement in markers of free radical reducing capacity but no clinical benefit (assessments included the Short Form 36 Health Survey (SF-36) questionnaire and UK Medical Research Council (MRC) muscle strength, in 13 participants).

Authors' conclusions: Despite identifying eight new trials there is currently no clear evidence supporting the use of any intervention in mitochondrial disorders. Further research is needed to establish the role of a wide range of therapeutic approaches. We suggest further research should identify novel agents to be tested in homogeneous study populations with clinically relevant primary endpoints.

PubMed Disclaimer

Conflict of interest statement

Patrick Chinnery: none known.

Kari Majamaa: has received funding for travel from Octapharma and Lundbeck and speaker honoraria from OrionPharma.

Gerald Pfeffer: is the recipient of funding from the Clinician Investigator Program from the University of British Columbia in Vancouver, Canada, and a Bisby fellowship from the Canadian Institutes of Health Research. He reports no competing interests.

David Thorburn: none known.

Douglass Turnbull: our work was supported by The Wellcome Trust Centre for Mitochondrial Research (906919), the Newcastle University Centre for Brain Ageing and Vitality supported by BBSRC, EPSRC, ESRC and MRC as part of the cross‐council Lifelong Health and Wellbeing Initiative (G0700718)

Figures

1
1
Risk of bias summary: review authors' judgements about each risk of bias item for each included study.
See this image and copyright information in PMC

Update of

References

References to studies included in this review

DeStefano 1995 {published data only}
    1. DeStefano N, Matthews PM, Ford B, Genge A, Karpati G, Arnold DL. Short‐term dichloracetate treatment improves indices of cerebral metabolism in patients with mitochondrial disorders. Neurology 1995;45(6):1193‐8. [PUBMED: 7783888] - PubMed
Duncan 2004 {published data only}
    1. Duncan GE, Perkins LA, Theriaque DW, Neiberger RE, Stacpoole PW. Dichloroacetate therapy attenuates the blood lactate response to submaximal exercise in patients with defects in mitochondrial energy metabolism. Journal of Clinical Endocrinology and Metabolism 2004;89(4):1733‐8. [PUBMED: 15070938] - PubMed
Glover 2010 {published data only}
    1. Glover EI, Martin J, Maher A, Thornhill RE, Moran GR, Tarnopolsky MA. A randomized trial of coenzyme Q10 in mitochondrial disorders. Muscle & Nerve 2010;42(5):739‐48. [PUBMED: 20886510] - PubMed
Kaufmann 2006 {published data only}
    1. Kaufmann P, Engelstad K, Wei Y, Jhung S, Sano MC, Shungu DC, et al. Dichloroacetate causes toxic neuropathy in MELAS. Neurology 2006;66(3):324‐30. [PUBMED: 16476929] - PubMed
Klopstock 2000 {published data only}
    1. Klopstock T, Querner V, Schmidt F, Gekeler F, Walter M, Hartard M, et al. A placebo‐controlled crossover trial of creatine in mitochondrial diseases. Neurology 2000;55(11):1748‐51. [PUBMED: 11113239] - PubMed
Kornblum 2005 {published data only}
    1. Kornblum C, Schröder R, Müller K, Vorgerd M, Eggers J, Bogdanow M, et al. Creatine has no beneficial effect on skeletal muscle energy metabolism in patients with single mitochondrial deletions: a placebo‐controlled, double‐blind 31P‐MRS crossover study. European Journal of Neurology 2005;12(4):300‐9. [PUBMED: 15804248] - PubMed
Liet 2003 {published data only}
    1. Liet JM, Pelletier V, Robinson BH, Laryea MD, Wendel U, Morneau S, et al. The effect of short‐term dimethylglycine treatment on oxygen consumption in cytochrome oxidase deficiency: a double‐blind randomized crossover clinical trial. Journal of Pediatrics 2003;142(1):62‐6. [PUBMED: 12520257] - PubMed
Mancuso 2010 {published data only}
    1. Mancuso M, Orsucci D, LoGerfo A, Rocchi A, Petrozzi L, Nesti C, et al. Oxidative stress biomarkers in mitochondrial myopathies, basally and after cysteine donor supplementation. Journal of Neurology 2010;257(5):774‐781. - PubMed
Rodriguez 2007 {published data only}
    1. Rodriguez MC, MacDonald JR, Mahoney DJ, Parise G, Beal MF, Tarnopolsky MA. Beneficial effects of creatine, CoQ10, and lipoic acid in mitochondrial disorders. Muscle & Nerve 2007;35(2):235‐42. [PUBMED: 17080429] - PubMed
Stacpoole 2006 {published data only}
    1. Stacpoole PW, Kerr DS, Barnes C, Bunch ST, Carney PR, Fennell EM, et al. Controlled clinical trial of dichloroacetate for treatment of congenital lactic acidosis in children. Pediatrics 2006;117(5):1519‐31. [PUBMED: 16651305] - PubMed
Tarnopolsky 1997 {published data only}
    1. Tarnopolsky MA, Roy BD, MacDonald JR. A randomized controlled trial of creatine monohydrate in patients with mitochondrial cytopathies. Muscle & Nerve 1997;20(12):1502‐9. [PUBMED: 9390662] - PubMed
Vissing 2001 {published data only}
    1. Vissing J, Gansted U, Quistorff B. Exercise intolerance in mitochondrial myopathy is not related to lactic acidosis. Annals of Neurology 2001;49(5):672‐6. [PUBMED: 11357960] - PubMed

References to studies excluded from this review

Bresolin 1990 {published data only}
    1. Bresolin N, Doriguzzi C, Ponzetto C, Angelini C, Moroni I, Castelli E, et al. Ubidecarenone in the treatment of mitochondrial myopathies: a multi‐center double‐blind trial. Journal of the Neurological Sciences 1990;100(1‐2):70‐8. [PUBMED: 2089142] - PubMed
Cejudo 2005 {published data only}
    1. Cejudo P, Bautista J, Montemayor T, Villagómez R, Jiménez L, Ortega F, et al. Exercise training in mitochondrial myopathy: a randomized controlled trial. Muscle & Nerve 2005;32(3):342‐50. [PUBMED: 15962332] - PubMed
Chen 1997 {published data only}
    1. Chen RS, Huang CC, Chu NS. Coenzyme Q10 treatment in mitochondrial encephalomyopathies. Short‐term double‐blind, crossover study. European Neurology 1997;37(4):212‐8. [PUBMED: 9208260] - PubMed
Gimenes 2007 {published data only}
    1. AC Gimenes, LM Nápolis, NL Silva, GO Siqueira, CR Nogueira, AS Bulle, et al. The effects of L‐carnitine supplementation on respiratory muscle strength and exercise tolerance in patients with mitochondrial myopathies [Abstract]. European Respiratory Journal 2007;Suppl 51:21S[E297].
Koga 2005 {published data only}
    1. Koga Y, Akita Y, Nishioka J, Yatsuga S, Povalko N, Tanabe Y, et al. L‐arginine improves the symptoms of strokelike episodes in MELAS. Neurology 2005;64(4):710‐2. [PUBMED: 15728297] - PubMed
Muller 1990 {published data only}
    1. Muller W, Reimers CD, Berninger T, Boergen K‐P, Frey A, Zrenner E, et al. Coenzyme Q10 in ophthalmoplegia plus ‐ a double blind, cross over therapeutic trial. Journal of the Neurological Sciences 1990;98 Supplement:442.
Stacpoole 2008 {published data only}
    1. Stacpoole PW, Gilbert LR, Neiberger RE, Carney PR, Valenstein E, Theriaque DW, et al. Evaluation of long‐term treatment of children with congenital lactic acidosis with dichloroacetate. Pediatrics 2008;121(5):e1223‐8. [PUBMED: 18411236] - PMC - PubMed
Suzuki 1998 {published data only}
    1. Suzuki S, Hinokio Y, Ohtomo M, Hirai M, Hirai A, Chiba M, et al. The effects of coenzyme Q10 treatment on maternally inherited diabetes mellitus and deafness, and mitochondrial DNA 3243 (A to G) mutation. Diabetologia 1998;41(5):584‐8. [PUBMED: 9628277] - PubMed
Taivassalo 2006 {published data only}
    1. Taivassalo T, Gardner JL, Taylor RW, Schaefer AM, Newman J, Barron MJ, et al. Endurance training and detraining in mitochondrial myopathies due to single large‐scale mtDNA deletions. Brain 2006;129(Pt 12):3391‐401. [PUBMED: 17085458] - PubMed

Additional references

Abe 1991
    1. Abe K, Fujimura H, Nishikawa Y, Yorifuji S, Mezaki T, Hirono N, et al. Marked reduction in CSF lactate and pyruvate levels after CoQ therapy in a patient with mitochondrial myopathy, encephalopathy, lactic acidosis and stroke‐like episodes (MELAS). Acta Neurologica Scandinavica 1991;83(6):356‐9. - PubMed
Abe 1999
    1. Abe K, Matsuo Y, Kadekawa J, Inoue S, Yanagihara T. Effect of coenzyme Q10 in patients with mitochondrial myopathy, encephalopathy, lactic acidosis, and stroke‐like episodes (MELAS): evaluation by noninvasive tissue oximetry. Journal of the Neurological Sciences 1999;162(1):65‐8. - PubMed
Anderson 1981
    1. Anderson S, Bankier AT, Barrell BG, Bruijn MH, Coulson AR, Drouin J, et al. Sequence and organization of the human mitochondrial genome. Nature 1981;290(5806):457‐65. - PubMed
Barbiroli 1995
    1. Barbiroli B, Montagna P, Cortelli P, Iotti S, Lodi R, Barboni P, et al. Lipoic (thioctic) acid increases brain energy availability and skeletal muscle performance as shown by in vivo 31P‐MRS in a patient with mitochondrial cytopathy. Journal of Neurology 1995;242(7):472‐7. - PubMed
Barshop 2004
    1. Barshop BA, Naviaux RK, McGowan KA, Levine F, Nyhan WL, Loupis‐Geller A, et al. Chronic treatment of mitochondrial disease patients with dichloroacetate. Molecular Genetics and Metabolism 2004;83(1‐2):138‐49. - PubMed
Bendahan 1992
    1. Bendahan D, Desnuelle C, Vanuxem D, Confort‐Gouny S, Figarella‐Branger D, Pellissier JF, et al. 31P NMR spectroscopy and ergometer exercise test as evidence for muscle oxidative performance improvement with coenzyme Q in mitochondrial myopathies. Neurology 1992;42(6):1203‐8. - PubMed
Bernsen 1993
    1. Bernsen PL, Gabreels FJ, Ruitenbeek W, Hamburger HL. Treatment of complex I deficiency with riboflavin. Journal of the Neurological Sciences 1993;118(2):181‐7. - PubMed
Chinnery 1997
    1. Chinnery PF, Turnbull DM. Clinical features, investigation and management of patients with defects of mitochondrial DNA. Journal of Neurology, Neurosurgery and Psychiatry 1997;63(5):559‐63. - PMC - PubMed
Chinnery 1998
    1. Chinnery PF, Howell N, Lightowlers RN, Turnbull DM. Genetic counseling and prenatal diagnosis for mtDNA disease. American Journal of Human Genetics 1998;63(6):1908‐11. - PMC - PubMed
Chinnery 2001
    1. Chinnery PF, Turnbull DM. Epidemiology and treatment of mitochondrial disease. American Journal of Medical Genetics 2001;106(1):94‐101. - PubMed
Cortelli 1997
    1. Cortelli P, Montagna P, Pierangeli G, Lodi R, Barboni P, Liguori R, et al. Clinical and brain bioenergetics improvement with idebenone in a patient with Leber's hereditary optic neuropathy: a clinical and 31P‐MRS study. Journal of the Neurological Sciences 1997;148(1):25‐31. - PubMed
Curless 1986
    1. Curless RG, Flynn J, Bachynski B, Gregorios JB, Benke P, Cullen R. Fatal metabolic acidosis, hyperglycemia, and coma after steroid therapy for Kearns‐Sayre syndrome. Neurology 1986;36(6):872‐3. - PubMed
DiMauro 1998
    1. DiMauro S, Schon EA. Nuclear power and mitochondrial disease. Nature Genetics 1998;19(3):214‐5. - PubMed
DiMauro 2001
    1. DiMauro S, Schon EA. Mitochondrial DNA mutations in human disease. American Journal of Medical Genetics 2001;106(1):18‐26. - PubMed
DiMauro 2003
    1. DiMauro S, Schon EA. Mitochondrial respiratory‐chain diseases. New England Journal of Medicine 2003;348(26):2656‐68. - PubMed
Eleff 1984
    1. Eleff S, Kennaway NG, Buist NR, Darley‐Usmar VM, Capaldi RA, Bank WJ, et al. 31P NMR study of improvement in oxidative phosphorylation by vitamins K3 and C in a patient with a defect in electron transport at complex III in skeletal muscle. Proceedings of the National Academy of Sciences of the United States of America 1984;81(11):3529‐33. - PMC - PubMed
Gold 1996
    1. Gold R, Seibel P, Reinelt G, Schinder R, Landwehr P, Beck A, et al. Phosphorus magnetic resonance spectroscopy in the evaluation of mitochondrial myopathies: results of a 6‐month therapy study with coenzyme Q. European Neurology 1996;36(4):191‐6. - PubMed
Gubbay 1989
    1. Gubbay SS, Hankey GJ, Tan NT, Fry JM. Mitochondrial encephalomyopathy with corticosteroid dependence. The Medical Journal of Australia 1989;151(2):100‐8, 10. - PubMed
Hassani 2010
    1. Hassani A, Horvath R, Chinnery PF. Mitochondrial myopathies: developments in treatment. Current Opinion in Neurology 2010;23(5):459‐65. - PubMed
Higgins 2011
    1. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org.
Holt 1988
    1. Holt IJ, Harding AE, Morgan‐Hughes JA. Deletion of muscle mitochondrial DNA in patients with mitochondrial myopathies. Nature 1988;331(6158):717‐9. - PubMed
Hsu 1995
    1. Hsu CC, Chuang YH, Tsai JL, Jang HJ, Shen YY, Huang HL, et al. CPEO and carnitine deficiency overlapping in MELAS syndrome. Acta Neurologica Scandinavica 1995;92(3):252‐5. - PubMed
Ihara 1989
    1. Ihara Y, Namba R, Kuroda S, Sato T, Shirabe T. Mitochondrial encephalomyopathy (MELAS): pathological study and successful therapy with coenzyme Q10 and idebenone. Journal of the Neurological Sciences 1989;90(3):263‐71. - PubMed
Jeppesen 2006
    1. Jeppesen TD, Schwartz M, Olsen DB, Wibrand F, Krag T, Dunø M, et al. Aerobic training is safe and improves exercise capacity in patients with mitochondrial myopathy. Brain 2006;129(Pt 12):3402‐12. - PubMed
Kaukonen 2000
    1. Kaukonen J, Juselius JK, Tiranti V, Kyttala A, Zeviani M, Comi GP, et al. Role of adenine nucleotide translocator 1 in mtDNA maintenance. Science 2000;289(5480):782‐5. - PubMed
Kurlemann 1995
    1. Kurlemann G, Paetzke I, Maler H, Masur H, Schuierer G, Weglage J, et al. Therapy of complex I deficiency: peripheral neuropathy during dichloracetate therapy. European Journal of Pediatrics 1995;154(11):928‐32. - PubMed
Lamantea 2002
    1. Lamantea E, Tiranti V, Bordoni A, Toscano A, Bono F, Servidei S, et al. Mutations of mitochondrial DNA polymerase gammaA are a frequent cause of autosomal dominant or recessive progressive external ophthalmoplegia. Annals of Neurology 2002;52(2):211‐9. - PubMed
Leonard 2000
    1. Leonard JV, Schapira AVH. Mitochondrial respiratory chain disorders I: mitochondrial DNA defects. Lancet 2000;355(9200):299‐304. - PubMed
Lou 1981
    1. Lou HC. Correction of increased plasma pyruvate and plasma lactate levels using large doses of thiamine in a patient with Kearns‐Sayre syndrome. Archives of Neurology 1981;38(7):469. - PubMed
Macmillan 1993
    1. Macmillan C, Lach B, Shoubridge EA. Variable distribution of mutant mitochondrial DNAs (tRNA(Leu[3243])) in tissues of symptomatic relatives with MELAS: the role of mitotic segregation. Neurology 1993;43(8):1586‐90. - PubMed
Majamaa 1997
    1. Majamaa K, Rusanen H, Remes A, Hassinen IE. Metabolic interventions against complex I deficiency in MELAS syndrome. Molecular and Cellular Biochemistry 1997;174(1‐2):291‐6. - PubMed
Mandel 2001
    1. Mandel H, Szargel R, Labay V, Elpeleg O, Saada A, Shalata A. The deoxyguanosine kinase gene is mutated in individuals with depleted hepatocerebral mitochondrial DNA. Nature Genetics 2001;29(3):337‐41. - PubMed
Mashima 1992
    1. Mashima Y, Hiida Y, Oguchi Y. Remission of Leber's hereditary optic neuropathy with idebenone [letter]. Lancet 1992;340(8815):368‐9. [PUBMED: 1353825] - PubMed
Mashima 2000
    1. Mashima Y, Kigasawa K, Wakakura M, Oguchi Y. Do idebenone and vitamin therapy shorten the time to achieve visual recovery in Leber hereditary optic neuropathy?. Journal of Neuro‐Ophthalmology 2000;20(3):166‐70. - PubMed
Mathews 1993
    1. Mathews PM, Andermann F, Silver K, Karpati G, Arnold DL. Proton MR spectroscopic characterization of differences in regional brain metabolic abnormalities in mitochondrial encephalomyopathies. Neurology 1993;43(12):2484‐90. - PubMed
Mitsui 2002
    1. Mitsui T, Umaki Y, Nagaswa M, Akaike M, Aki K, Azuma H, et al. Mitochondrial damage in patients with long‐term corticosteroid therapy: development of oculoskeletal symptoms similar to mitochondrial disease. Acta Neuropathologica 2002;104(3):260‐6. - PubMed
Montini 2008
    1. Montini G, Malaventura C, Salviati L. Early coenzyme Q10 supplementation in primary coenzyme Q10 deficiency. New England Journal of Medicine 2008;358(26):2849‐50. - PubMed
Mootha 2003
    1. Mootha VK, Lepage P, Miller K, Bunkenborg J, Reich M, Hjerrild M, et al. Identification of a gene causing human cytochrome c oxidase deficiency by integrative genomics. Proceedings of the National Academy of Sciences of the United States of America 2003;100(2):605‐10. - PMC - PubMed
Moraes 1989
    1. Moraes CT, DiMauro S, Zeviani M, Lombes A, Shanske S, Miranda AF, et al. Mitochondrial DNA deletions in progressive external ophthalmoplegia and Kearns‐Sayre syndrome. New England Journal of Medicine 1989;320(20):1293‐9. - PubMed
Mori 2004
    1. Mori M, Yamagata T, Goto T, Saito S, Momoi MY. Dichloroacetate treatment for mitochondrial cytopathy: long‐term effects in MELAS. Brain & Development 2004;26(7):453‐8. - PubMed
Mowat 1999
    1. Mowat D, Kirby DM, Kamatu KR, Kan A, Thorburn DR, Christodoulou J. Respiratory chain complex III deficiency with pruritis: a novel vitamin responsive clinical feature. Journal of Pediatrics 1999;134(3):352‐4. - PubMed
Murphy 2008
    1. Murphy JL, Blakely EL, Schaefer AM, He L, Wyrick P, Haller RG. Resistance training in patients with single, large‐scale deletions of mitochondrial DNA. Brain 2008;131(Pt 11):2832‐40. - PubMed
Musumeci 2001
    1. Musumeci O, Naini A, Slonim AE, Skavin N, Hadjigeorgiou GL, Krawiecki N, et al. Familial cerebellar ataxia with muscle coenzyme Q10 deficiency. Neurology 2001;56(7):849‐55. - PubMed
Naviaux 2004
    1. Naviaux RK, Nguyenk V. POLG mutations associated with Alpers' syndrome and mitochondrial DNA depletion. Annals of Neurology 2004;55(5):706‐12. - PubMed
Nishikawa 1989
    1. Nishikawa K, Takahashi M, Yorifuji S, Nakamura Y, Veno S, Tarui S, et al. Long‐term coenzyme Q10 therapy for a mitochondrial encephalomyopathy with cytochrome c oxidase deficiency: a 31P NMR study. Neurology 1989;39(3):399‐403. - PubMed
Nishino 1999
    1. Nishino I, Spinazzola A, Hirano M. Thymidine phosphorylase gene mutations in MNGIE, a human mitochondrial disorder. Science 1999;283(5402):689‐92. - PubMed
Ogasahara 1986
    1. Ogasahara S, Nishikawa Y, Yorifuji S, Soga F Nakamura Y, Takahashi M, et al. Treatment of Kearns‐Sayre syndrome with coenzyme Q10. Neurology 1986;36(1):45‐53. - PubMed
Ogasahara 1989
    1. Ogasahara S, Engel AG, Frens D, Mack D. Muscle coenzyme Q deficiency in familial mitochondrial encephalomyopathy. Proceedings of the National Academy of Sciences of the United States of America 1989;86(7):2379‐82. - PMC - PubMed
Oguro 2004
    1. Oguro H, Iijima K, Takahasi K, Nagai A, Bokwa H, Yamaguchi S, et al. Successful treatment with succinate in a patient with MELAS. Internal Medicine 2004;43(5):427‐31. - PubMed
Panetta 2004
    1. Panetta J, Smith LJ, Boneh A. Effect of high‐dose vitamins, coenzyme Q and high‐fat diet in paediatric patients with mitochondrial diseases. Journal of Inherited Metabolic Disease 2004;27(4):487‐98. - PubMed
Papadimitriou 1996
    1. Papadimitriou A, Hadjigeorgiou GM, Divavi R, Pagagalanis N, Comi G, Bresolin N. The influence of coenzyme Q10 on total serum calcium concentration in two patients with Kearns‐Sayre syndrome and hypoparathyroidism. Neuromuscular Disorders 1996;6(1):49‐53. - PubMed
Penn 1992
    1. Penn AM, Lee JW, Thuillier P, Wagner M, Machire KM Menard MR, et al. MELAS syndrome with mitochondrial tRNA(Leu)(UUR) mutation: correlation of clinical state, nerve conduction, and muscle 31P magnetic resonance spectroscopy during treatment with nicotinamide and riboflavin. Neurology 1992;42(11):2147‐52. - PubMed
Remes 2002
    1. Remes AM, Liimatta EV, Winqvist S, Tolonen U, Ranua JA, Reinikaineuk, et al. Ubiquinone and nicotinamide treatment of patients with the 3243A‐‐>G mtDNA mutation. Neurology 2002;59(8):1275‐7. - PubMed
Rotig 2000
    1. Rotig A, Appelkvist EL, Geromel V, Chretien D, Kadahan N, Edery P, et al. Quinone‐responsive multiple respiratory chain deficiency due to widespread coenzyme Q10 deficiency. Lancet 2000;356(9227):391‐5. - PubMed
Saada 2001
    1. Saada A, Shaag A, Mandel H, Nevo Y, Eriksson S, Elpeleg O. Mutant mitochondrial thymidine kinase in mitochondrial DNA depletion myopathy. Nature Genetics 2001;29(3):342‐4. - PubMed
Schaefer 2008
    1. Schaefer AM, McFarland R, Blakely EL, He L, Whittaker RG. Prevalence of mitochondrial DNA disease in adults. Annals of Neurology 2008;63(1):35‐9. - PubMed
Schapira 2006
    1. Schapira AH. Mitochondrial disease. Lancet 2006;368(9529):70‐82. - PubMed
Schon 1997
    1. Schon EA, Bonilla E, DiMauro S. Mitochondrial DNA mutations and pathogenesis. Journal of Bioenergetics and Biomembranes 1997;29(2):131‐49. - PubMed
Shoffner 1989
    1. Shoffner JM, Lott MT, Voljavec AS, Soueidan SA, Costigan DA, Wallace DC. Spontaneous Kearn‐Sayre/chronic external ophthalmoplegia plus syndromes associated with a mitochondrial DNA deletion: a slip‐replication model and metabolic therapy. Proceedings of the National Academy of Sciences of the United States of America 1989;86(20):7952‐6. - PMC - PubMed
Sobreira 1997
    1. Sobreira C, Hirano M, Shanske S, Keller RK, Haller RG, Davidson E, et al. Mitochondrial encephalomyopathy with coenzyme Q10 deficiency. Neurology 1997;48(5):1238‐43. - PubMed
Spelbrink 2001
    1. Spelbrink JN, Li FY, Tiranti V, Nikali K, Yuan QP, Tariq M, et al. Human mitochondrial DNA deletions associated with mutations in the gene encoding Twinkle, a phage T7 gene 4‐like protein localised in mitochondria. Nature Genetics 2001;28(3):223‐31. - PubMed
Spinazzola 2009
    1. Spinazzola A, Zeviani M. Mitochondrial diseases: a cross‐talk between mitochondrial and nuclear genomes. Advances in Experimental Medicine and Biology 2009;652:69‐84. - PubMed
Taivassalo 1998
    1. Taivassalo T, Stefano N, Argov Z, Matthews PM, Chen J, Genge A, et al. Effects of aerobic training in patients with mitochondrial myopathies. Neurology 1998;50(4):1055‐60. - PubMed
Taivassalo 2001
    1. Taivassalo T, Shoubridge EA, Chen J, Kennaway NG, Dimauro S, Arnold DL, et al. Aerobic conditioning in patients with mitochondrial myopathies: physiological, biochemical, and genetic effects. Annals of Neurology 2001;50(2):133‐41. - PubMed
Tarnopolsky 1999
    1. Tarnopolsky M, Martin J. Creatine monohydrate increases strength in patients with neuromuscular disease. Neurology 1999;52(4):854‐7. - PubMed
Tucker 2010
    1. Tucker EJ, Compton AG, Thorburn DR. Recent advances in the genetics of mitochondrial encephalomyopathies. Current Neurology and Neuroscience Reports 2010;10(4):277–85. - PubMed
Van Goethem 2001
    1. Goethem G, Dermaut B, Lofgren A, Martin JJ, Broeckhoven C. Mutation of POLG is associated with progressive external ophthalmoplegia characterized by mtDNA deletions. Nature Genetics 2001;28(3):211‐2. - PubMed
Wallace 1994
    1. Wallace DC. Mitochondrial DNA mutations in diseases of energy metabolism. Journal of Bioenergetics & Biomembranes 1994;26(3):241‐50. - PubMed
Wallace 1999
    1. Wallace DC. Mitochondrial diseases in mouse and man. Science 1999;283(5407):1482‐8. - PubMed
Westermann 2010
    1. Westermann B. Mitochondrial fusion and fission in cell life and death. Nature Reviews Molecular Cell Biology 2010;11(12):872‐4. - PubMed
Zeviani 1988
    1. Zeviani M, Moraes CT, DiMauro S, Nakase H, Bonilla E, Schon EA, et al. Deletions of mitochondrial DNA in Kearns‐Sayre syndrome. Neurology 1988;38(9):1339‐46. - PubMed
Zhu 2009
    1. Zhu X, Peng X, Guan MX, Yan Q. Pathogenic mutations of nuclear genes associated with mitochondrial disorders. Acta Biochimica et Biophysica Sinica 2009;41(3):179‐87. - PubMed

References to other published versions of this review

Chinnery 2006
    1. Chinnery P, Majamaa K, Turnbull D, Thorburn D. Treatment for mitochondrial disorders. Cochrane Database of Systematic Reviews 2006, Issue 1. [DOI: 10.1002/14651858.CD004426.pub2] - DOI - PubMed

Publication types

MeSH terms